Importantly, this new drug has been shown to reduce synaptic degeneration and improve the disease phenotype of a 3xTg AD mouse model (Talantova et al., 2013), a rat model of vascular dementia (Takahashi et al., 2015), a MEF2C haploinsufficiency mouse model of autism (Tu et al., 2017), a tuberous sclerosis mouse model (Okamoto et al., 2019) and an hAPP-J20 AD mouse model (Ghatak et al., 2020). The gene discussed is MEF2C; the disease is Alzheimer disease.